Publication | Closed Access
Effect of nitric oxide synthase inhibitors on bone metabolism in growing rats
50
Citations
0
References
1996
Year
PharmacotherapyOsteoporosisOxidative StressLumbar SpineOsteoarthritisMetabolismBone HomeostasisMineral MetabolismHealth SciencesAnimal PhysiologyBone HealthBone MassEndocrinologyPharmacologyBone MetabolismOsteocalcinChronic Nitric OxidePhysiologyMetabolic Bone DiseaseMedicine
We examined the effects of chronic nitric oxide (NO) blockade on bone mineral status in growing rats. Oral administration of NG-nitro-L-arginine methyl ester (L-NAME) for 4 wk caused hypertension and a significant reduction in urinary NO2- and NO3- excretion. Four-week oral aminoguanidine (AG, 400 mg/dl of drinking water) did not alter blood pressure but caused a significant decrease in urinary NO2- and NO3-. Rats treated with L-NAME at doses of 20 and 50 mg/dl had normal bone mineral mass in the lumbar spine, but the highest dose (80 mg/dl) caused a slight decrease in bone mass. Chronic AG induced a significant spine osteopenia. This effect of AG was abolished by the simultaneous administration of L-arginine (2.0 g/dl). AG-induced osteopenia was associated with a significant increase in urine excretion of collagen cross-links with normal serum osteocalcin. These findings indicate that chronic AG administration can cause an imbalance between bone resorption and formation, resulting in a decrease in bone mass in growing rats, and suggest that NO produced by inducible NO synthase plays an important role in basal osteoclast bone degradation activity in vivo.